ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
ADC Therapeutics S.A.NYSE: ADCT
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items declines year over year
Q1 FY2026 other non-cash items of $5.71M fell 33.3% year over year, ahead of the -86.0% change in trailing-twelve-month other non-cash items. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Other non-cash items amounted to 22.2% of revenue in FY2025, down 6.6 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -86.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 18.02M USD
- Year-over-year change
- -11.4%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.02M | -11.4% |
| FY2024 | 2024-12-31 | 20.34M | -12.4% |
| FY2023 | 2023-12-31 | 23.23M | +102.4% |
| FY2022 | 2022-12-31 | 11.48M | +146.5% |
| FY2021 | 2021-12-31 | (24.7M) | — |
Other Non-Cash Items vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 other non-cash items of $2.88M is the 7th largest of the 10 companies compared; the peer median is $569K.
- Its year-over-year change of -86.0% is the lowest of 10, against a peer median of +167.4%.
- Other non-cash items amounts to 3.6% of revenue for ADCT, versus a peer median of 39.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $217.51M | +1659.6% | — | 2198.6% | |
| LTM Mar 2026 | $47.4M | +606.5% | +135.3% | 320.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $44.46M | +123.1% | +1204.6% | 601.0% |
| LTM Mar 2026 | $30.75M | +1982.5% | — | 48.4% | |
| LTM Mar 2026 | $13.16M | +395.9% | +33.8% | 14.2% | |
| LTM Mar 2026 | $4.55M | -40.8% | — | 5.2% | |
| LTM Mar 2026 | $2.88M | -86.0% | +16.2% | 3.6% | |
| LTM Mar 2026 | $1.69M | +118.0% | — | 2.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.66M | +167.4% | -60.9% | — |
| LTM Mar 2026 | $569K | +107.2% | — | 30.7% | |
| Peer median (excluding ADCT) | $569K | +167.4% | +84.5% | 39.6% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Depreciation & Amortization | 2.63M | 5.74M | 3.27M | 3.28M | 1.88M |
| Deferred Income Tax | (26.05M) | 0 | 37.1M | 0 | 0 |
| Stock-Based Compensation | 60.48M | 50.64M | 13.5M | 6.57M | 6.91M |
| Change in Working Capital | (15.71M) | (49.04M) | 44.27M | 3.83M | (25.36M) |
| Accounts Receivables | (30.22M) | (42.75M) | 47.79M | 4.77M | (8.79M) |
| Inventory | (3.02M) | (9.65M) | (5.71M) | (3.73M) | (2.38M) |
| Accounts Payables | 6.8M | 310K | 3.17M | 2.46M | (9.04M) |
| Other Working Capital | 10.73M | 3.37M | (979K) | 321K | (5.15M) |
| Other Non-Cash Items | (24.7M) | 11.48M | 23.23M | 20.34M | 18.02M |
| Operating Cash Flow | (233.38M) | (138.31M) | (118.69M) | (123.84M) | (141.17M) |
| Capital Expenditures | (6.38M) | (687K) | (3.22M) | (867K) | (264K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 659K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.24M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.67M) | (687K) | (3.22M) | (867K) | 395K |
| Debt Repayment | 48.61M | (2.71M) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 60.51M | 152.46M |
| Common Stock Repurchased | 0 | (1.32M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 218.78M | 3.13M | 73.88M | 36.55M | (1.51M) |
| Financing Cash Flow | 267.39M | (897K) | 73.88M | 97.05M | 150.95M |
| Effect of Forex Changes | 6K | (208K) | 184K | (83K) | 305K |
| Net Change in Cash | 27.35M | (140.1M) | (47.84M) | (27.73M) | 10.47M |
| Free Cash Flow | (239.75M) | (139M) | (121.9M) | (124.7M) | (141.44M) |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.